ERYTECH Selects Triple Negative Breast Cancer as Next Indication for Eryaspase

  • Post author:
  • Post category:Newsroom

LYON, France – February 13, 2018 – ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the selection of Triple Negative Breast Cancer as the next target indication for broadening the scope of eryaspase (GRASPA®) development in solid tumors.

Menu